Overcoming Obstacles in HCV 2017

 

HCV 17 Overcoming HCV Banner


HCV 17 Button

About the Program

Program Overview

Chronic hepatitis C (CHC) afflicts millions of people in the United States.  It is a significant public health issue, because CHC can evolve into states that are associated with cirrhosis, hepatic fibrosis and hepatocellular carcinoma (HCC). The incidence of deaths from HCV infections is increasing, and, since 2007, the number of people who die from HCV infection in the United States each year has exceeded the numbers who die from HIV infection.  While significant progress has been made in the treatment of CHC, many clinicians with HCV infected patients are not aware of the full range of complex and emerging management and treatment options available or how to apply them to various patient scenarios.  Furthermore, infected patients are going undiagnosed due to lack of education and resources surrounding screening and diagnostic testing for CHC.  Due to the rapidly changing landscape of CHC management, these issues can significantly affect the treatment of patients with HCV infection and the quality of the care they receive, potentially affecting patient outcomes, increasing morbidity, mortality and treatment costs.  

This online program entitled, "Overcoming Obstacles in HCV: Improving the Detection, Evaluation and Treatment of HCV-infected Individuals," consists of case-based modules that feature a panel of HCV thought leaders who review and discuss the most critical aspects of HCV prevention, management and treatment.  Each presentation focuses on a different approach or population involved in HCV care.  The information and opinions provided are intended to improve a clinician's ability to prevent, diagnose and manage HCV infection.  Participants who complete these modules will gain increased understanding of the optimal management skills needed to treat various types of patients with CHC, which is expected to result in improved patient care, reduces morbidity and mortality, reduced costs and meaningful improvement in patient outcomes.

Back to Top

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be better able to:

  • Improve the rate of testing and diagnosis of patients with CHC
  • Link patients with diagnosed CHC to timely and appropriate HCV therapy
  • Provide optimal, individualized HCV therapy to patients with CHC that results in improved outcomes

Release Date: September 13, 2017

Expiration Date: September 13, 2018

Estimated time to complete each Module:  30-45 minutes

Media: Internet

Back to Top

Course Directors

Paul Kwo, MD
Director of Hepatology
Professor of Medicine
Stanford University School of Medicine
Palo Alto, California
Tram Tran, MD
Medical Director
Liver Transplant
Cedars Sinai Los Angeles
Los Angeles, California

Faculty

Oluwatoyin M. Adeyemi, MD
Associate Professor of Medicine
Rush Medical College
Attending Physician of Infectious Diseases
Cook County Health and Hospitals System
Chicago, Illinois
Mark Sulkowski, MD
Professor of Medicine and
Medical Director
Viral Hepatitis Center
Johns Hopkins University
School of Medicine
Baltimore, Maryland

Back to Top

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ per module. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There are 6 modules available for a total of 3.00 possible credit hours.  

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

 

Oluwatoyin M. Adeyemi, MD
  • Consulting Fees: Gilead, ViiV
  • Contracted Research: Gilead, AbbVie
Paul Kwo, MD
  • Consulting Fees: Abbvie, Quest, CVS, BMS, Gilead, Janssen, Merck, Alnylam
  • Contracted Research: Abbvie, BMS, Gilead, Janssen, Merck, Contanus, ESAI
  • Other (DSMB): Inovio
Mark Sulkowski, MD
  • Contracted Research (to JHU): Abbvie, Gilead, Merck, Tobira
  • Consulting Fees: Abbvie, CoCrystal, Gilead, Merck, Trek
  • Other: Gilead - DSMB Member
Tram Tran, MD
  • Consulting Fees: AbbVie, Gilead, Merck
  • Contracted Research: AbbVie, Gilead, Merck
  • Feeds for Non-CME?CE Services Recieved Directly from a Commercial Interest or thier Agents (e.g., speakers' bureaus: Abbvie, Gilead, Merck

 

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. 

Back to Top 

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. During the period, September 13, 2017 through September 13, 2018, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 12595 . Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

 

    PIM_small

 

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs

 

 

Back to Top

 

Prepare to print

Share this page:

Get link code to this page                     


Back to Top